feed
view company updates
tools
perform investment research
network
join events & discussions
advisory
about us
Redeye Capital
Alzecure: Håller tidplan med ACD440
Research Note
2020-12-07
11:12
Redeye ser positivt på att Alzecure möter sitt mål om att inleda två kliniska fas 1-studier innan årets slut.
AH
Anders Hedlund
Sign up for free to continue
Sign up with Email
Sign in with Google
Already a member?
Sign in
Disclosures and disclaimers
Premium Plan required to unlock
Unlock companies to access
more high quality research.
View Plans